Novartis’ Enablex Given Green Light for Clinical Trials By China’s SFDA
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China's State FDA has officially accepted BMP Sunstone's clinical trial application for Novartis' Enablex (darifenacin), the company announced May 6.
You may also be interested in...
Sanofi Expands China Footprint In OTC And Rx Markets With BMP Sunstone Acquisition
Sanofi-Aventis has gained a leadership position in China's OTC cough/cold market with its $520.6 million acquisition of BMP Sunstone, the latest in the global pharma's parade of consumer health buys
Sanofi Expands China Footprint In OTC And Rx Markets With BMP Sunstone Acquisition
Sanofi-Aventis has gained a leadership position in China's OTC cough/cold market with its $520.6 million acquisition of BMP Sunstone, the latest in the global pharma's parade of consumer health buys
Novartis’ Paul Herrling And En Li On R&D Strategy In China, India And The Pacific Rim: An Interview With PharmAsia News (Part 2 of 2)
[Editor's Note: This is part two of a two-part interview. Part one appeared May 4, 2008 in PharmAsia News.]